Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P160008/S035

HeartSine samaritan (SAM) Public Access Defibrillator (PAD) SAM 350P, SAM 360P and SAM 450P and Accessories

HeartSine Technologies Ltd · Decision date Jun 22, 2026

FDA DECISIONP160008/S035

What did the FDA decide?

FDA records P160008/S035 as a supplement to PMA P160008, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 22, 2026.

FDA approval order statement

a battery supplier manufacturing site change
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Jun 22, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P160008/S035
Regulatory pathway
PMA supplement
Product code
MKJ
Decision code
OK30
Decision date
Jun 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Automated external defibrillators (non-wearable).

Product code
MKJ
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P160008/S028 · Related supplement

    HeartSine Technologies LLC's samaritan Public Access Automated External Defibrillators (SAM 350P, SAM 360P and SAM 450P)

  2. P160008/S029 · Related supplement

    HeartSines samaritan Public Access Automated External Defibrillators (SAM 350P, SAM 360P and SAM 450P) and Accessories

  3. P160008/S027 · Related supplement

    HeartSine samaritan Public Access Automated External Defibrillators (SAM 350P, SAM 360P and SAM 450P) and Accessories

  4. P160008/S030 · Related supplement

    HeartSine Technologies LLC's samaritan Public Access Automated External Defibrillators (SAM 350P, SAM 360P and SAM 450P)

  5. P160008/S031 · Related supplement

    samaritan Public Access Automated External Defibrillators (SAM 350P, SAM 360P and SAM 450P) and Accessories

  6. P160008/S032 · Related supplement

    HeartSines samaritan Public Access Automated External Defibrillators (SAM 350P, SAM 360P and SAM 450P) and Accessories

  7. P160008/S033 · Related supplement

    HeartSines samaritan Public Access Automated External Defibrillators (SAM 350P, SAM 360P and SAM 450P) and Accessories

  8. P160008/S034 · Related supplement

    HeartSine samaritan Public Access Automated External Defibrillators (SAM 350P, SAM 360P and SAM 450P) and Accessories

  9. P160008/S035 received

    Application receipt date recorded by FDA.

  10. P160008/S035 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P160008. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160008

Product / regulatory recordCompanyPathwayDecision dateSource
HeartSine Technologies LtdPMA supplementAug 27, 2025FDA
HeartSine Technologies LtdPMA supplementSep 2, 2025FDA
HeartSine Technologies LtdPMA supplementSep 17, 2025FDA
HeartSine Technologies LtdPMA supplementSep 29, 2025FDA
HeartSine Technologies LtdPMA supplementDec 22, 2025FDA
HeartSine Technologies LtdPMA supplementJan 8, 2026FDA
HeartSine Technologies LtdPMA supplementMay 7, 2026FDA
HeartSine Technologies LtdPMA supplementMay 18, 2026FDA

Explore the linked device profile

Other records with product code MKJ

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

HeartSine Technologies Ltd

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
207 Airport Rd. W., Belfast, BT3 9ED

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records